NO20081198L - Fremgangsmate for a predikere eller monitorere en pasients respons til et medikament rettet mot en ErbB-reseptor - Google Patents

Fremgangsmate for a predikere eller monitorere en pasients respons til et medikament rettet mot en ErbB-reseptor

Info

Publication number
NO20081198L
NO20081198L NO20081198A NO20081198A NO20081198L NO 20081198 L NO20081198 L NO 20081198L NO 20081198 A NO20081198 A NO 20081198A NO 20081198 A NO20081198 A NO 20081198A NO 20081198 L NO20081198 L NO 20081198L
Authority
NO
Norway
Prior art keywords
patient
predicting
monitoring
procedure
response
Prior art date
Application number
NO20081198A
Other languages
English (en)
Inventor
Kazuto Nishio
Hideharu Kimura
Kazuo Kasahara
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO20081198L publication Critical patent/NO20081198L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det omtales ved oppfinnelsen en framgangsmåte for detektering av ErbB-reseptormutasjoner som omfatter trinnene at det frambringes en bio-fluidprøve fra en pasient, DNA avtrekkes fra prøven, og DNA screenes for nærvær av én eller flere mutasjoner som endrer tyrosinkinaseaktiviteten i reseptoren.
NO20081198A 2005-10-05 2008-03-06 Fremgangsmate for a predikere eller monitorere en pasients respons til et medikament rettet mot en ErbB-reseptor NO20081198L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2005003823 2005-10-05
PCT/GB2005/004036 WO2007039705A1 (en) 2005-10-05 2005-10-20 Method to predict or monitor the response of a patient to an erbb receptor drug

Publications (1)

Publication Number Publication Date
NO20081198L true NO20081198L (no) 2008-06-30

Family

ID=36114238

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081198A NO20081198L (no) 2005-10-05 2008-03-06 Fremgangsmate for a predikere eller monitorere en pasients respons til et medikament rettet mot en ErbB-reseptor

Country Status (14)

Country Link
US (1) US20080286785A1 (no)
EP (1) EP1931798A1 (no)
JP (1) JP2009511008A (no)
KR (1) KR20080028857A (no)
CN (1) CN101351563A (no)
AU (1) AU2005337051A1 (no)
BR (1) BRPI0520530A2 (no)
CA (1) CA2624613A1 (no)
IL (1) IL189705A0 (no)
NO (1) NO20081198L (no)
NZ (1) NZ566387A (no)
TW (1) TW200714716A (no)
WO (1) WO2007039705A1 (no)
ZA (1) ZA200802854B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
WO2010017163A1 (en) 2008-08-04 2010-02-11 Wyeth Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
BRPI0917871A2 (pt) 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
KR20140036332A (ko) 2009-04-06 2014-03-25 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
ES2628219T3 (es) * 2009-05-19 2017-08-02 Vivia Biotech S.L. Métodos para proporcionar ensayos de medicina personalizada ex vivo para neoplasias hematológicas
WO2011058164A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
JP5931736B2 (ja) * 2009-11-13 2016-06-08 ウー３・フアルマ・ゲー・エム・ベー・ハーＵ３ Ｐｈａｒｍａ Ｈｅｒ−３関連疾患を治療または予防するための物質および方法
EP2859893A1 (en) 2010-03-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
EP2447378B1 (en) * 2010-10-29 2017-06-21 ARKRAY, Inc. Probe for detection of polymorphism in EGFR gene, amplification primer, and use thereof
WO2012065071A2 (en) * 2010-11-12 2012-05-18 The Broad Institute Of Mit And Harvard Methods of predicting response to egfr antibody therapy
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
CN107419018B (zh) * 2012-02-16 2020-09-04 江苏宏微特斯医药科技有限公司 一种基于Blocker引物和ARMS引物检测基因突变的方法和试剂盒
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
WO2014135669A1 (en) * 2013-03-08 2014-09-12 Roche Diagnostics Gmbh Egfr mutation blood testing
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US9994914B2 (en) 2014-10-09 2018-06-12 Roche Molecular Systems, Inc. Mutation in the epidermal growth factor receptor kinase domain
GB201507202D0 (en) 2015-04-28 2015-06-10 Stfc Science & Technology Receptor tyosine kinase biomarkers
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP6899504B2 (ja) * 2017-01-10 2021-07-07 ゼジアン ジャーチ デベロップメント ファーマシューティカルズ リミテッド 膜開始エストロゲンシグナルのラソフォキシフェンでのモジュレーションおよび腫瘍の治療方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9403953D0 (sv) * 1994-07-15 1994-11-16 Pharmacia Biotech Ab Sequence-based diagnosis
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
GB9812768D0 (en) * 1998-06-13 1998-08-12 Zeneca Ltd Methods
EP1730306A2 (en) * 2004-03-01 2006-12-13 University of Chicago Polymorphisms in the epidermal growth factor receptor gene promoter
KR101289774B1 (ko) * 2004-03-31 2013-08-07 다나-파버 캔서 인스티튜트 인크. 표피성장인자 수용체를 표적으로 하는 치료에 대한 암의반응성을 결정하는 방법
US7932026B2 (en) * 2004-06-04 2011-04-26 Genentech, Inc. EGFR mutations
GB2424886A (en) * 2005-04-04 2006-10-11 Dxs Ltd Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
US20060223178A1 (en) * 2005-04-05 2006-10-05 Tom Barber Devices and methods for magnetic enrichment of cells and other particles

Also Published As

Publication number Publication date
AU2005337051A1 (en) 2007-04-12
KR20080028857A (ko) 2008-04-01
US20080286785A1 (en) 2008-11-20
WO2007039705A1 (en) 2007-04-12
NZ566387A (en) 2010-05-28
IL189705A0 (en) 2008-06-05
JP2009511008A (ja) 2009-03-19
ZA200802854B (en) 2009-06-24
BRPI0520530A2 (pt) 2009-09-29
CA2624613A1 (en) 2007-04-12
TW200714716A (en) 2007-04-16
CN101351563A (zh) 2009-01-21
EP1931798A1 (en) 2008-06-18

Similar Documents

Publication Publication Date Title
NO20081198L (no) Fremgangsmate for a predikere eller monitorere en pasients respons til et medikament rettet mot en ErbB-reseptor
MX361882B (es) Deteccion en tiempo real de virus de influenza.
WO2007070376A8 (en) Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis
GB2477053B (en) Droplet-based assay system
WO2005076887A3 (en) Methods and systems for sampling, screening, and diagnosis
IL210065A0 (en) Improved method and system for detecting and/or predicting biological anomalies, such as cerebral disorders
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
WO2009117122A3 (en) Genetic analysis
DK1421215T3 (da) Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
WO2007093819A3 (en) Dna conformation (loop structures) in normal and abnormal gene expression
WO2006044078A3 (en) Apparatus and method for analysis of molecules
ES2422735T3 (es) Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502
WO2001040517A3 (en) Evaluating and predicting clinical outcomes by gene expression analysis
ATE527543T1 (de) Testvorrichtung zur schnelldiagnose
WO2004096985A3 (en) Methods for assessing biologic diversity
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2008112567A3 (en) Method and apparatus for quantitative assessment of neuromotor disorders
WO2005121362A3 (en) Method for selectively quantifying vegf isoforms in a biological sample and uses thereof.
ATE537271T1 (de) Toll-like-rezeptor-4-dysfunktion und biologische anwendungen davon
WO2019204340A3 (en) Biomarker for predicting equine gait and methods of use thereof
SE0402731D0 (sv) Liquid detection and confidence determination
WO2008145701A9 (en) Method for predicting the outcome of a critically ill patient
DK2274623T3 (da) Fremgangsmåde til diagnosticering af pulmonal arteriel hypertension
WO2005056839A3 (de) Primer und sonden zum nachweis genitaler hpv-genotypen
NO20072615L (no) Biomarkor for hjertesvikt

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application